Technology Review: Gene Editing
Edition one of Phacilitate’s Technology review series examines gene editing approaches by viral and no-viral methods and where to access these services
read morePeople & Career | News |
Edition one of Phacilitate’s Technology review series examines gene editing approaches by viral and no-viral methods and where to access these services
read moreThe discussion moves onto goes onto the fine line between success and failure, examining the stories of Apollo 13, Thomas Edison and Elizabeth Gilbert, the author of Eat. Pray. Love. Dwayne explores failure and its negative connotations. Failure provides an opportunity to learn and to display passion to others, it’s an iteration on the road to success. In the immortal words of the great Thomas Edison
read moreWith a swell of R&D activity flowing into the development of cell and gene therapies over the past decade, a manufacturing shortage gripped the industry. This caused industry participants to express grave fears that the manufacturing shortage would threaten industry growth and lengthen time-to-market for these new types of living therapies
read moreÈ di pochi giorni fa la notizia dell’approvazione negli Stati Uniti di una terapia genica per l’atrofia muscolare spinale
read moreBluebird Bio Inc.’s first gene therapy, a treatment for an inherited blood disorder, was cleared by European Union regulators, another milestone for the field following U.S. approval of Novartis AG’s $2.1 million treatment for a lethal childhood disease
read moreA comprehensive guide to Europe’s growing advanced therapies and viral vector manufacturing landscape
read moreCRO, CMO, CDMO. These acronyms are well known in the biotech and pharma industry. But what is a BMO? If you haven’t heard of it, don’t worry. After all, there is only one BMO worldwide. We have set out to discover more about it, this biotech manufacturing organization
read moreL’Italia come Hub internazionale per le terapie avanzate. Uno scenario di sfide e opportunitá
read moreAnemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961